Login / Signup

Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.

Christopher F BellAnna D CoutinhoEileen FarrellyTasneem LokhandwalaPamela Landsman-Blumberg
Published in: Journal of medical economics (2018)
Few clinical and economic differences between subjects initiating maintenance therapy with FSC or TIO were observed.
Keyphrases
  • chronic obstructive pulmonary disease
  • healthcare
  • stem cells
  • quality improvement
  • adipose tissue
  • metabolic syndrome
  • insulin resistance
  • bone marrow
  • cell therapy
  • replacement therapy
  • air pollution
  • weight loss